Delic Corp Announces Participation Details For January 2022 Investor Conferences
Delic Corp announced the participation of CEO Matt Stang at two significant investor conferences: the HC Wainwright Bioconnect Virtual Conference from January 10-13, 2022, and the CEM's 8th Annual AlphaNorth Capital Conference from January 21-23, 2022. Stang will discuss the company's expansion strategy and outlook on the psychedelic industry, as well as engage in one-on-one meetings with investors. Delic focuses on psychedelic wellness and operates several related businesses, enhancing access to health benefits through innovative treatments.
- Participation in two notable investor conferences may increase visibility and networking opportunities for Delic.
- Stang's presentations are likely to highlight the company's growth potential in the psychedelic sector.
- None.
Matt Stang, Co-founder and CEO of Delic Corp, Will Present the Company's Strategic Outlook at HC Wainwright Bioconnect Virtual Conference Jan 10-13 and CEM's 8th Annual AlphaNorth Capital Conference Jan 21-23
VANCOUVER, BC, Dec. 9, 2021 /PRNewswire/ - Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced details regarding Matt Stang, co-founder and CEO of Delic, and his participation at the upcoming HC Wainwright Bioconnect Virtual Conference and CEM's 8th annual AlphaNorth Capital Conference in January.
- HC Wainwright Bioconnect Virtual Conference
January 10-13, 2022
He will present on the company's expansion strategy and industry outlook heading into the new year and offer one-on-one meetings with investors. To access Delic's presentation at the virtual HC Wainwright Bioconnect Conference and sign up for a one-on-one meeting, please visit https://hcwevents.com/bioconnect/ to register for the four-day event. - CEM's 8th Annual AlphaNorth Capital Conference
January 21-23, 2022
Located at the beautiful Grand Hyatt Baha Mar in Nassau, Bahamas, the conference connects growth-stage companies in sectors including technology and biotech with top-level capital finance individuals. Stang will host one-on-one meetings that take a closer look at the company's growth opportunities in the upcoming year. Investors and issuers interested in registering for the attendee waitlist can visit https://cem.ca/conference/alphanorth-capital-event/.
About Delic Corp
Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, including Ketamine Infusion Centers and Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Forward-Looking Information and Statements
This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction; anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.
By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.
In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; the ability of the parties to obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of other conditions to the consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the Transaction.
Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.
Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.
View original content to download multimedia:https://www.prnewswire.com/news-releases/delic-corp-announces-participation-details-for-january-2022-investor-conferences-301440817.html
SOURCE Delic Holdings Inc.
FAQ
What is the significance of Delic's participation in the HC Wainwright Bioconnect Virtual Conference?
When will Delic Corp present at the CEM's 8th Annual AlphaNorth Capital Conference?
What topics will Matt Stang discuss at the upcoming investor conferences?
What is Delic Corp known for?
Are there any upcoming presentations or conferences for Delic?
